Italia markets closed

Kala Pharmaceuticals, Inc. (0JQ2.L)

LSE - LSE Prezzo differito. Valuta in USD.
Aggiungi a portafoglio
1,7320+0,0020 (+0,12%)
Alla chiusura: 05:07PM GMT

Kala Pharmaceuticals, Inc.

490 Arsenal Way
Suite 120
Watertown, MA 02472
United States
781 996 5252
https://www.kalarx.com

Settore/i
Settore
Impiegati a tempo pieno188

Figure dirigenziali chiave

NomeTitoloRetribuzioneEsercitateAnno di nascita
Mr. Mark T. IwickiChairman, Pres & CEO1,27MN/D1966
Mr. Todd BazemoreChief Operating Officer739,54kN/D1970
Dr. Kim BrazzellChief Medical Officer848,27kN/D1953
Dr. Justin Hanes Ph.D.Founder & Chair of the Scientific Advisory BoardN/DN/DN/D
Ms. Mary Reumuth CPA, CPACFO & TreasurerN/DN/D1975
Dr. Hongming Chen Sc.D.Chief Scientific OfficerN/DN/D1971
Ms. Jill S. SteierExec. Director of Investor Relations & Corp. CommunicationsN/DN/DN/D
Mr. Eric L. TrachtenbergGen. Counsel, Chief Compliance Officer & Corp. Sec.N/DN/D1973
Ms. Kathleen McCann KlineSr. VP of MarketingN/DN/DN/D
Ms. Michele LaRussaSr. VP of Regulatory Affairs & Quality AssuranceN/DN/D1970
Gli importi risalgono al giorno 31 dicembre 2020 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies using its proprietary nanoparticle-based Mucus Penetrating Particles (MPP) technology for the treatment of eye diseases. The company's product candidates include EYSUVIS for the short-term treatment of the signs and symptoms of dry eye disease; and INVELTYS, a topical twice-a-day ocular steroid for the treatment of post-operative inflammation and pain following ocular surgery. Its preclinical development programs comprise KPI-285/KPI-286, a receptor tyrosine kinase inhibitor program for the treatment of various retinal diseases; SEGRM program, a novel class of compounds designed to regulate gene expression through the transrepression pathway while avoiding the transactivation pathway; and surface targeted steroid program (KPI-333), a new chemical entity as a topical steroid that targets the ocular surface. The company was formerly known as Hanes Newco, Inc. and changed its name to Kala Pharmaceuticals, Inc. in December 2009. Kala Pharmaceuticals, Inc. was incorporated in 2009 and is headquartered in Watertown, Massachusetts.

Governance aziendale

L'ISS Governance QualityScore di Kala Pharmaceuticals, Inc. al 26 settembre 2021 è 10. I criteri di valutazione fondamentali sono revisione: 7; Consiglio di Amministrazione: 10; diritti degli azionisti: 9; retribuzione: 8.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.